High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study.
Jesús Loarce-Martos,Antía García-Fernández,Fernando López-Gutiérrez,Verónica García-García,Laura Calvo-Sanz,Iván Del Bosque-Granero,M Andreína Terán-Tinedo,Alina Boteanu,J. Bachiller-Corral,Mónica Vázquez-Díaz +9 more
Reads0
Chats0
TLDR
Treatment with rituximab should be considered a possible risk factor for unfavorable outcomes in COVID-19 patients with RMD, with a high rate of severe disease requiring hospitalization and a high mortality rate.Abstract:
The objective of this study is to describe the characteristics and outcomes of rheumatic and musculoskeletal disease (RMD) patients who were treated with rituximab and had suspected or confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In this descriptive study, RMD patients who were treated with rituximab in the last 12 months at the Rheumatology Department of our hospital were screened for SARS-CoV-2 infection via telephone interview and a comprehensive review of clinical health records (01/02/2020-26/05/2020). Those with probable or confirmed SARS-CoV-2 infection were included. In total, 76 patients were screened. Of these, 13 (17.1%) had suspected or confirmed SARS-CoV-2 infection. With regard to these 13 patients, the median age at coronavirus disease (COVID-19) diagnosis was 68 years (range 28-76 years) and 8 (61.5%) were female. Five patients had rheumatoid arthritis, three had systemic vasculitis, two had Sjogren syndrome, and two had systemic lupus erythematosus. Additionally, seven patients (53.8%) had pulmonary involvement secondary to RMD. Eight patients (61.5%) developed severe disease leading to hospitalization, and seven developed bilateral pneumonia and respiratory insufficiency. Of the eight hospitalized patients, five (62.5%) fulfilled the acute respiratory distress syndrome criteria and three developed a critical disease and died. Our cohort had a high rate of severe disease requiring hospitalization (61.5%), with bilateral pneumonia and hyperinflammation leading to a high mortality rate (23.1%). Treatment with rituximab should be considered a possible risk factor for unfavorable outcomes in COVID-19 patients with RMD. However, further study is required to confirm this association.read more
Citations
More filters
Journal ArticleDOI
Humoral immune response following SARS-CoV-2 mRNA vaccination concomitant to anti-CD20 therapy in multiple sclerosis.
Frederik Novak,Anna Nilsson,Christian Nielsen,Dorte Kinggaard Holm,Kamilla Østergaard,Anna Bystrup,Keld-Erik Byg,Isik Somuncu Johansen,Kristen Mittl,William Rowles,Kira Mcpolin,Collin M. Spencer,Sharon A. Sagan,Chloe Gerungan,Michael R. Wilson,Scott S. Zamvil,Riley Bove,Joseph J. Sabatino,Tobias Sejbaek +18 more
TL;DR: Novak et al. as mentioned in this paper investigated the immunogenicity of COVID-19 vaccine among patients receiving anti-CD20 monoclonal antibody (Ab) treatment and showed decreased humoral response after BNT162b2 mRNA SARS-CoV-2 vaccine in MS patients receiving B-cell depleting therapy.
Journal ArticleDOI
Coronavirus disease 2019 (COVID-19) and immune-mediated rheumatic diseases. Recommendations of the association of rheumatologists of Russia
E. L. Nasonov,A. M. Lila,Vadim I. Mazurov,B. S. Belov,A. E. Karateev,Tatiana Dubinina,O. A. Nikitinskaya,A. A. Baranov,Diana Abdulganieva,S. V. Moiseev,A. I. Zagrebneva +10 more
TL;DR: The new version of the recommendations of the Association of Rheumatologists of Russia formulates the main provisions concerning the tactics of managing patients with Immune-mediated Rheumatic Diseases during the ongoing COVID-19 pandemic.
Journal ArticleDOI
COVID-19 in Patients Receiving CD20-depleting Immunochemotherapy for B-cell Lymphoma
Erik Gaitzsch,Verena Passerini,Elham Khatamzas,Carolin Strobl,Maximilian Muenchhoff,Clemens Scherer,Andreas Osterman,Michael Heide,Anna Reischer,Marion Subklewe,Marion Subklewe,Alexandra Leutbecher,Benjamin Tast,Adrian Ruhle,Tobias Weiglein,Stephanie-Susanne Stecher,Hans Joachim Stemmler,Martin Dreyling,Philipp Girl,Enrico Georgi,Roman Wölfel,Laura Mateyka,Elvira D’Ippolito,Kilian Schober,Dirk H. Busch,Juliane Kager,Christoph D. Spinner,Matthias Treiber,Sebastian Rasch,Tobias Lahmer,Roman Iakoubov,Jochen Schneider,Ulrike Protzer,Ulrike Protzer,Christof Winter,Christof Winter,Jürgen Ruland,Jürgen Ruland,Michael Quante,Michael Quante,Oliver T. Keppler,Michael von Bergwelt-Baildon,Michael von Bergwelt-Baildon,Johannes C. Hellmuth,Johannes C. Hellmuth,Oliver Weigert,Oliver Weigert +46 more
TL;DR: In this article, the clinical and immunological impact of B-cell depletion in the context of coronavirus disease 2019 (COVID-19) is unclear, and the authors conducted a prospectively planned analysis of COVID-2019 in patients who received B-cells depleting anti-CD20 antibodies and chemotherapy for b-cell lymphomas.
Journal ArticleDOI
Harnessing Type I IFN Immunity Against SARS-CoV-2 with Early Administration of IFN-β.
Donald C. Vinh,Laurent Abel,Laurent Abel,Laurent Abel,Paul Bastard,Paul Bastard,Paul Bastard,Matthew P. Cheng,Antonio Condino-Neto,Peter K. Gregersen,Filomeen Haerynck,Maria-Pia Cicalese,David Hagin,Pere Soler-Palacín,Anna M. Planas,Aurora Pujol,Luigi D. Notarangelo,Qian Zhang,Helen C. Su,Jean-Laurent Casanova,Isabelle Meyts +20 more
TL;DR: In this article, I.M.C.N. is a Senior Clinical Investigator at the Research Foundation -Flanders, and is chair of the CSL Behring Chair of Primary Immunodeficiency at KU Leuven, by the KU-Leuven C1 Grant C16/18/007, by a VIB GC PID Grant, by FWO Grants G0C8517N, G0B5120N, and G0E8420N.
Journal ArticleDOI
COVID-19 in B Cell-Depleted Patients After Rituximab: A Diagnostic and Therapeutic Challenge.
Anna Furlan,Gabriella Forner,Ludovica Cipriani,Elisa Vian,Roberto Rigoli,Filippo Gherlinzoni,Piergiorgio Scotton +6 more
TL;DR: In this paper, the effects of anti-CD20 treatment on B cell functions involved in anti-SARS-CoV-2 immunity and significantly impacts on the clinical and serological course of SARS infection, long term immunity and vaccine responses are discussed.
References
More filters
Journal ArticleDOI
Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry.
Milena A. Gianfrancesco,Kimme L. Hyrich,Sarah Al-Adely,Loreto Carmona,Maria I. Danila,Maria I. Danila,Laure Gossec,Zara Izadi,Lindsay Jacobsohn,Patricia P. Katz,Saskia Lawson-Tovey,Elsa F Mateus,Stephanie Rush,Gabriela Schmajuk,Julia F. Simard,Anja Strangfeld,Laura Trupin,Katherine D Wysham,Suleman Bhana,Wendy Costello,Rebecca Grainger,Jonathan S. Hausmann,Jonathan S. Hausmann,Jean W. Liew,Emily Sirotich,Paul Sufka,Zachary S. Wallace,Jinoos Yazdany,Pedro Machado,Philip Robinson,Philip Robinson +30 more
TL;DR: It is found that glucocorticoid exposure of ≥10 mg/day is associated with a higher odds of hospitalisation and anti-TNF with a decreased odds ofospitalisation in patients with rheumatic disease.
Journal ArticleDOI
Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies.
Sara Monti,Silvia Balduzzi,Paolo Delvino,E. Bellis,Verdiana Serena Quadrelli,Carlomaurizio Montecucco +5 more
TL;DR: The survey investigated the patients’ health conditions, the presence of contacts with subjects known to be affected by COVID-19 and management of patients with chronic arthritis treated with biological disease-modifying antirheumatic drugs followed up at the biological outpatient clinic in Pavia, Lombardy.
Journal ArticleDOI
Covid-19 in Immune-Mediated Inflammatory Diseases - Case Series from New York.
Rebecca H. Haberman,Jordan E. Axelrad,Alan Chen,Rochelle Castillo,Di Yan,Peter M. Izmirly,Andrea L. Neimann,Samrachana Adhikari,David Hudesman,Jose U. Scher +9 more
TL;DR: Patients in New York City with known immune-mediated inflammatory disease in whom Covid-19 developed while they were receiving treatment with the drug are described.
Journal ArticleDOI
Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US 'hot spot'.
Kristin M. D’Silva,Naomi Serling-Boyd,Rachel Wallwork,Tiffany Y.T. Hsu,Xiaoqing Fu,Ellen M. Gravallese,Hyon K. Choi,Jeffrey A. Sparks,Zachary S. Wallace +8 more
TL;DR: Patients with rheumatic disease and COVID-19 infection were more likely to require mechanical ventilation but had similar clinical features and hospitalisation rates as those without rhematic disease.
Journal ArticleDOI
Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs.
Xabier Michelena,Xabier Michelena,Helena Borrell,Mireia López-Corbeto,María López-Lasanta,Estefanía Moreno,María Pascual-Pastor,Alba Erra,Mayte Serrat,Esther Espartal,Susana Antón,Gustavo Adolfo Añez,Raquel Caparrós-Ruiz,Andrea Pluma,Ernesto Trallero-Araguás,Mireia Barceló-Bru,Miriam Almirall,Juan José De Agustín,Jordi Lladós,Antonio Julià,Sara Marsal +20 more
TL;DR: Adult and paediatric patients with rheumatic diseases on tDMARDs do not seem to present a higher risk of COVID-19 or a more severe disease outcome when compared to general population.
Related Papers (5)
Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry.
Milena A. Gianfrancesco,Kimme L. Hyrich,Sarah Al-Adely,Loreto Carmona,Maria I. Danila,Maria I. Danila,Laure Gossec,Zara Izadi,Lindsay Jacobsohn,Patricia P. Katz,Saskia Lawson-Tovey,Elsa F Mateus,Stephanie Rush,Gabriela Schmajuk,Julia F. Simard,Anja Strangfeld,Laura Trupin,Katherine D Wysham,Suleman Bhana,Wendy Costello,Rebecca Grainger,Jonathan S. Hausmann,Jonathan S. Hausmann,Jean W. Liew,Emily Sirotich,Paul Sufka,Zachary S. Wallace,Jinoos Yazdany,Pedro Machado,Philip Robinson,Philip Robinson +30 more
Dexamethasone in Hospitalized Patients with Covid-19
Peter Horby,Wei Shen Lim,Jonathan Emberson,M Mafham,Jennifer L Bell,Louise Linsell,Natalie Staplin,Christopher E. Brightling,Andrew Ustianowski,E Elmahi,B Prudon,Christopher A Green,Timothy Felton,David Chadwick,K Rege,C Fegan,Lucy C Chappell,Saul N. Faust,Thomas Jaki,Katie Jeffery,Alan A Montgomery,Kathryn M Rowan,Edmund Juszczak,J K Baillie,Richard Haynes,Martin J Landray +25 more
Factors associated with COVID-19-related death using OpenSAFELY.
Elizabeth A. Williamson,Alex J Walker,Krishnan Bhaskaran,Seb Bacon,Chris Bates,Caroline E Morton,Helen J Curtis,Amir Mehrkar,David M. Evans,Peter Inglesby,Jonathan Cockburn,Helen Mcdonald,Brian MacKenna,Laurie A. Tomlinson,Ian J. Douglas,Christopher T Rentsch,Rohini Mathur,Angel Y S Wong,Richard Grieve,David G. Harrison,Harriet Forbes,Anna Schultze,Richard Croker,John Parry,Frank Hester,Sam Harper,Rafael Perera,Stephen J. W. Evans,Liam Smeeth,Ben Goldacre +29 more